Abstract The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related 
Introduction
Inflammatory breast cancer (IBC) is a clinical diagnosis designated as T4d disease in the TNM classification of the American Joint Committee on Cancer [1] . IBC is distinct from neglected, locally advanced breast cancer with a clinical course characterized by a rapid course of progression featuring local growth and early metastasis. IBC is a rare breast cancer that accounts for 1-5% of all breast cancers in the United States [2, 3] . Several authors have analyzed gene expression profiles of IBC to evaluate peculiar features of this disease [4] [5] [6] [7] . Van Laere et al. reported that the insulin-like growth factor-signaling pathway is implicated in the biology of IBC [7] . Nguyen et al. reported that IBC has higher expression of genes associated with increased metabolic rate, lipid signaling, and cell turnover [6] . All previous studies compared IBC with non-IBC simply on the bases of clinical diagnosis and without considering molecular subtypes of breast disease. However, breast cancer is no longer considered to be a single disease with variable receptor expression and histology but rather as a collection of several distinct diseases distinguished by unique clinical, biological, and molecular features. These molecular and clinical subtypes can be discerned in both IBC and non-IBC.
We hypothesized that there are biological differences between IBC and non-IBC tumors according to each clinical subtype, including ER-positive/HER2-normal, HER2-amplified with any ER status, and ER-negative/HER2-normal cancers. We tested this hypothesis at the individual gene level and at the level of gene sets that represent biological functions by comparing IBC and non-IBC within each clinical subtype. We also studied survival for patients with IBC and non-IBC tumors matched by clinical subtype.
Materials and methods

Patient cohorts and gene expression data
Tumor biopsies were collected prospectively from patients with locally advanced disease who were candidates for neoadjuvant therapy. Fine needle aspiration (FNA) was obtained before administration of any systemic therapy as part of an ongoing pharmacogenomic research program at The University of Texas MD Anderson Cancer Center. All patients gave written informed consent for voluntary participation. The study was approved by the Institutional Review Board. Samples were placed in RNAlater (Ambion, Austin, TX) storage reagent and stored at -80°C until gene expression analysis. This study followed a case-control design. Patients with a clinical diagnosis of IBC were selected after reviewing all medical records associated with the 440 FNA samples with complete gene expression data. Data were collected between 2000 and 2007. IBC was defined as the presence of erythema and edema (peau d'orange) involving at least one-third of the skin of the breast and rapid clinical presentation and biopsy-proven invasive breast carcinoma. The presence of tumor emboli in the dermal lymphatics of the involved skin in the pathology report was not required for inclusion as IBC. Controls were selected to match the T stage, with all T4a-c tumors in the data set included as controls. We identified 25 IBCs and 57 non-IBC controls for this analysis. Clinicopathologic characteristics of the patient cohorts are presented in Table 1 .
Gene expression profiling was performed using Affymetrix U133A gene chips as previously described [8] . Gene expression data were normalized with the MAS5 algorithm, mean centered to 600 and log 2 transformed before further analysis. Probe sets with the lowest 15% mean expression value were removed from all higher level analyses to reduce noise from low expressed probe sets. This left 18,940 probe sets for analysis. Cases with normalized ESR1 mRNA expression (probe set 205225_at) [10.18 were considered ER positive, and cases with HER-2 mRNA expression (probe set 216836_s_at) [12. 54 were considered HER2 amplified [9] . Molecular class was assigned based on gene expression profiles using the PAM 50 centroid-based classifier [10] . All statistical analysis was performed with BRB Array Tools version 3.9.0 Alfa software (http://linus.nci.nih.gov/BRB-ArrayTools.html) and R software version 2.7.2 (http://www.r-project.org). Complete gene expression data were deposited in the gene expression omnibus (GEO) data base under GSE22597.
Identification of differentially expressed genes and gene sets
We compared gene expression data between IBC and non-IBC tumors without any further stratification by clinical or molecular class using the t test. We also performed similar class comparisons separately for each of the three clinical subtypes [estrogen receptor (ER)-positive/Human Epidermal growth factor Receptor 2 (HER2)-normal, and ERnegative/HER2-normal, HER2-amplified]. To adjust for the multiple comparisons, we calculated false discovery rates (FDR) and also assessed Global Significance using BRB Array tools. The FDR was calculated with the significance analysis of microarrays (SAM) tool as the median number of false-positive genes from permutation testing divided by the number of nominally significant genes defined from the unperturbed data [11] . The Global P value is the probability of getting at least the same number of genes significant on a parametric test (e.g., t test) at the specified P level by chance if there are no real differences between IBC and non-IBC. Significantly differentially expressed genes were also mapped to functional pathways using the ingenuity pathway analysis software (IPA, http://www.ingenuity.com/). We also examined differential expression of a priori defined gene sets using gene set analysis (GSA). The goal of GSA is to determine whether members of a set of genes that correspond to a particular biological pathway tend to occur toward the top or the bottom of a rank-ordered gene list (rank ordered by differential expression between IBC vs. non-IBC) [12] . In this analysis, we included three gene sets that were previously reported to be discriminatory between IBC and non-IBC [4, 13, 14] or associated with poor prognosis in breast cancer, including a Wnt pathway gene set [15] and CD44? related stem cell signature [16] (Supplementary Table 1 ). We also tested 2,113 different, functionally annotated gene sets from gene ontology (GO, http://www.geneontology.org) that collectively represent most known biological and metabolic pathways in human cells. Gene sets with a minimum number of 10 genes and maximum of 100 genes were selected for inclusion in this analysis. We used the Efron and Tibshirani gene set analysis method that employs ''maxmean'' statistics and is implemented by the BRB Array Tools [17, 18] . Significance was estimated with the permutation test (n = 1,000). The null hypothesis was that the average degree of differential expression of members of a given gene set between the IBC and non-IBC cohorts is the same as expected from a random set of genes of similar size.
Survival analysis
Survival was estimated by the Kaplan-Meier product limit method and compared between groups with the log-rank statistic. Relapse-free survival was defined as the time from the diagnosis to local, regional, or distant relapse. Fourteen patients with stage IV disease (3 IBC and 11 non-IBC) and five additional patients who did not undergo surgery (1 IBC and 4 non-IBC, stage III disease) were excluded from the relapse-free survival analysis. Overall survival was defined as the time from the diagnosis to death, and all patients were included in this analysis.
Results
Differentially expressed genes between IBC and non-IBC
Clinical characteristics of the 82 patients included in this study are presented in Table 1 . The proportions of patients with lymphatic invasion (76 vs. 32%), ER-negative disease (76 vs. 46%), and HER2-amplified molecular class (40 vs. 26%) were greater in the IBC cohort than in the T stagematched non-IBC group. We first compared IBC with non-IBC regardless of their clinical subtypes. At any parametric P value threshold, the Global significance test indicated that the findings were not different from what could be expected by chance alone (Table 2) . Next, we performed the same analysis by clinical subtypes. Statistically significant differences using the Global test were observed in HER2-amplified cancers (Table 2; Supplementary Table 2 ). Five hundred and eight probe sets were differentially expressed between HER2-amplified IBC and non-IBC at parametric P B 0.01 (Global P = 0.04): 171 probe sets were overexpressed and 337 were underexpressed in IBC. However, the FDR rates associated with individual parametric P values ranged from 1.5 to 37%, indicating a substantial potential for false discovery among these genes. We mapped the 171 probe sets overexpressed in IBC to biological pathways, using Ingenuity Pathway Analysis. The top three pathways overexpressed in HER2-amplified IBC relative to non-IBC were eIF2 signaling, regulation of eIF4 and p70S6K signaling, and mammalian target of rapamycin (mTOR) signaling (Fig. 1a) . Silvera et al. have reported that eIF4GI reprograms the protein synthetic machinery for increased translation of mRNAs with internal ribosome entry sites that promote IBC tumor cell survival and formation of tumor emboli [19] .
GSA results
Individual gene (i.e., probe set) level analysis suggested relatively modest gene expression differences between IBC and non-IBC. Next, we investigated whether we could detect coordinated but relatively small scale differences in the expression of gene sets that belong to functional pathways. Such consistent but small-scale differences at the individual gene level may not be readily identified by t statistics but gene set enrichment analysis may be able to identify them. We tested five gene sets that were previously reported to be implicated in breast cancer prognosis or in the biology of IBC [4, [13] [14] [15] [16] . None of these previously published gene sets showed significant differential expression when all IBC cases were compared with all non-IBC (Table 2) . When comparisons were made within clinical subtypes, the IBC metagene by Bieche et al. [4] was significantly higher in ERpositive/HER2-normal IBC than in non-IBC of the same phenotype. The gene set by Bertucci et al. [14] was significantly higher in HER2-amplified IBC, and the CD44 stem cell signature had borderline significance. The Wnt gene set [15] was significantly overexpressed in ER-negative/HER2-normal IBC ( Table 2 ). The Wnt gene set was identified in a signature that discriminates lung metastases from primary tumor in SUM1315 orthotopic xenografts. Interestingly, SUM1315 breast cancer cells were initially isolated from a breast cancer skin metastasis [20] and were reported to correlation with basal breast cancer molecular subtypes [15] . To examine possible differences between IBC and non-IBC over a broad range of biological processes, we also tested 2,113 functionally annotated gene sets assembled from Gene Ontology. Many gene sets showed significant differential expression by IBC status within the three clinical subtypes [Supplementary Tables 3, 4 (1-4)]. At a P value of B0.01 (Efron-Tibshirani test), 28, 69, and 41 gene sets were differently expressed in ER-positive/HER2-normal, HER2-positive, and ER-negative/HER2-normal cancers, respectively. The gene sets that were significantly overexpressed in IBC in the three clinical subtypes are listed in Table 3 . We mapped all the members of these overexpressed gene sets (17, 33 , and 18 gene sets by each subtype) to biological pathways by IPA; the results are shown in Fig. 1b-d . In HER2-amplified IBC, the most significant pathways identified through GO were the same as those identified by the gene-by-gene analysis (Fig. 1a, b) . In ER-positive/HER2-normal IBC, the most significant pathways overexpressed in this subtype were the complement system, oncostatin signaling, and various immune cell-related pathways (Fig. 1c) . In the ER-negative/HER2-normal IBC specimens, Mycmediated apoptosis signaling, axonal guidance signaling, and Neuregulin signaling as well as some lipid metabolismrelated pathways were overexpressed. These results suggest that subtle biological differences may exist between breast cancer subtypes that show the inflammatory phenotype compared with tumors of the same subtype without inflammatory features. Interestingly, these differences seemed to vary by subtype.
Subtype-specific survival of IBC and non-IBC We examined whether the survival of patients with the three differs between IBC and non-IBC, with or without stratifying by clinical subtype. The median follow-ups were 53 months (range 18.5-89.8) and 57.2 months (range 9.6-112.5) for the IBC and non-IBC cohorts, respectively. In this case-control study, the overall survival results did not significantly differ for IBC and non-IBC, overall or within each clinical subset (data not shown). Among the IBC cases under consideration, 0 of 5 patients with ER-positive/HER2-normal tumors, 6 (50%) of 12 with HER2-positive, and 5 (62.5%) of 8 with ER-negative/HER2-normal had died. Among the non-IBC cases, 5 (22.7%) of 22 patients with ER-positive/HER2- * Global P value shows the probability of getting at least the same number of genes significant on a t test (at the specified P level) by chance if there are no real differences between IBC and non-IBC Breast Cancer Res Treat (2011) 125:785-795 789 normal tumors, 6 (35.3%) of 17 with HER2-positive, and 9 (50%) of 18 with ER-negative/HER2-normal had died. Relapse-free survival was worse in ER-negative/HER2-normal IBC patients than for the non-IBC of the same phenotype ( Supplementary Fig. 1 ). There was also no significant difference in overall or relapse-free survival by clinical subtype between the IBC and non-IBC cohorts (Fig. 2) . A trend was observed in both IBC and non-IBC for better survival in ER-positive/HER-normal cases, but the small sample limited the power of survival analysis by subtype. Also, survival analysis might have been affected by an imbalance for targeted therapy (trastuzumab: HER2 antibody). Six (50%) of 12 patients with HER2-amplified IBC and 11 (65%) of 17 patients with HER2-amplified non-IBC had never received either neoadjuvant or adjuvant therapy.
Discussion
This is the first study to systematically examine gene expression differences between IBC and non-IBC patients according to clinically relevant molecular subtypes defined based on ER and HER2 expression. Moreover, we also carefully matched the IBC and non-IBC cohorts for T stage. All patients in this analysis had clinical T4 and represented locally advanced breast cancer with and without inflammatory features. In a global comparison of IBC versus non-IBC, we detected no significant gene expression differences at the individual gene level between these two cohorts of cases after adjusting for multiple comparisons. This is in contrast to several published reports that found significant gene expression differences between IBC and non-IBC [4] [5] [6] [7] . This could probably be related to differences in the clinical characteristics of the comparison cohort. A closer analysis of the published literature reveals that many of the previous reports have not included stage II cancers in the comparison cohort [4, 5] . Some of the previous reports have not adjusted for multiple comparisons or used reverse transcription polymerase chain reaction (RT-PCR) to quantify gene expression differences, and RT-PCR has a different sensitivity and dynamic range of mRNA detection compared with gene expression arrays [4] . Importantly, all of these previous reports that suggested gene expression differences between IBC and non-IBC reported small-scale differences. One report assessed 538 genes and identified 22 that were differentially expressed [4] . Another report evaluated over 8,000 genes and found 105 that were differentially expressed [5] . A third report, similar to our analysis, found no significant differences at the individual gene level but observed some differences at the gene set level. [6] A fourth group of investigators tested close to 6,000 genes and found 50 that could discriminate between IBC and non-IBC [7] . When we tested these previously identified gene sets, we could only partially confirm the results from these publications in the current data set. Several of the gene sets were significantly overexpressed in IBC but only in particular clinical subtypes and not during a global comparison of all IBC with all non-IBC cohorts (as previously reported). This discrepancy reflects the unstable nature of these observations due to small and variable sample sizes of all current studies and the potential confounding effect of a variable clinical subtype distribution from study to study. The numbers of IBC cases included in the comparisons in published studies ranged from 14 to 37, and all previous analyses compared IBC with non-IBC without adjusting for molecular class or clinical receptor phenotype. Subtle imbalances in receptor phenotype between the IBC and non-IBC cohorts could lead to the identification of significantly differentially expressed genes that reflect the large-scale gene expression differences between molecular classes that were unevenly distributed across the two comparison cohorts, rather than the IBC-specific gene expression differences.
In the current study, we compared IBC and non-IBC after stratifying both groups into three clinically relevant subtypes of breast cancers. We found that individual gene level analysis showed significant differences only within the HER2-amplified group. Indeed, the natural history of HER2-amplified breast cancer has been dramatically changed by treatment with trastuzumab, an anti-HER2 antibody [21, 22] . This observation has also been noted in IBC [23] [24] [25] [26] [27] . Several studies have reported the efficacy of trastuzumab in the treatment of HER2-amplified IBC [23] [24] [25] [26] . Kaufman et al. reported that treatment with an EGFR/ HER2 tyrosine kinase inhibitor, lapatinib, provided clinical efficacy in HER2-amplified IBC during phase II trials [27] . For treatment of the other subtypes of IBC, no similar targeted drugs are available. We speculate the unique activity could stem from the different HER2 pathway involvement between IBC and non-IBC. In the other clinical subtypes, individual gene level analysis showed no significant differences.
When gene sets were tested for differential expression, different gene sets distinguished IBC from non-IBC in each clinical subtype (Fig. 1) . This suggests the possibility that different biological pathways are involved with the pathogenesis of the inflammatory phenotype in different molecular subsets of breast cancers. We found that complement and immune systems were highly associated with the ER-positive/HER2-normal IBC phenotype. Activation and regulation of complement pathways have been reported to play important roles in inflammatory mediators [28] . In addition, we found that protein translation and mTOR signaling were overexpressed in HER2-amplified tumors. mTOR, which functions downstream of the PI3K/Akt signaling pathway, is also being explored in therapies for HER2-amplified breast cancer [29] . mTOR inhibitors being tested in clinical trials for patients with breast cancer and other solid tumors include CCI-779 [30] , RAD001 [31] , and AP23573 [32] . We speculate that the importance of the mTOR pathway could be tested as potential target for HER2-amplified IBC by using one of the mTOR inhibitors. On the other hand, GSA showed that apoptosis, neural, and lipid metabolism pathways were overexpressed in ERnegative/HER2-normal IBC. There is biological plausibility to implicate these processes in IBC features. It is known that the neurotransmitter pathway and lipid metabolism play important roles in the regulation of cell migration and apoptosis [33] [34] [35] . These observations suggest the possibility of potential novel strategies to modulate ER-negative/HER2-normal IBC. However, the lack of overlap between the discriminating gene sets is also partly due to false-negative findings owing to the small sample sizes for each cohort, leading to limited power for detecting differentially expressed gene sets. Our data suggest that future studies involving IBC should consider the various clinical subtypes separately. These subtypes may have important clinical and molecular differences that justify their separate analysis. The different clinical prognoses of patients with the different clinical subtypes of breast cancer are well recognized, and similar differences in outcome may also exist among patients with IBC. This current study did not find any difference in overall survival related to different clinical subtypes of IBC, but we observed a worse relapse-free survival for patients with ER-negative/HER2-normal IBC compared with non-IBC of the same phenotype. However, this study was limited in its power to detect any but the most dramatic differences in survival because of the small sample size, which is due to the rarity of this disease entity (particularly when IBC is further subdivided by clinical phenotype). It may be necessary to create national and international cooperative networks to ensure sufficient sample sizes and homogeneous and mutually compatible analysis platforms for future studies of IBC.
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